Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients

Overview

The purpose of this study is to identify how certain parts of the brain that control appetite respond to changes in dietary carbohydrate and fat.

Full Title of Study: “Hypothalamic fMRI Response to Nutrients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 1, 2012

Detailed Description

To measure fMRI signal change in hypothalamic and brainstem centers associated with control of food intake and energy expenditure in response to IV glucose, fructose, and saline. The fMRI response to these nutrients will then be compared in obese vs. lean subjects. Frequently timed blood samples will be obtained for measurement of nutrients (i.e., glucose) and blood levels of other factors (i.e., insulin, ghrelin, lactate) during these infusion protocols, and to test associations between these levels and the fMRI response.

Interventions

  • Dietary Supplement: glucose
    • 0.3mg/kg of glucose
  • Dietary Supplement: fructose
    • fructose IV bolus
  • Dietary Supplement: saline
    • IV saline

Arms, Groups and Cohorts

  • Experimental: Glucose
    • IV glucose
  • Active Comparator: Fructose
  • Placebo Comparator: Saline

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcomes of this aim will be the change in fMRI response in the hypothalamus to IV glucose, to IV glucose during intralipid infusion, and to the IV glucose alone, in the lean and obese groups separately.
    • Time Frame: 0,1,2 and 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 year to 45 years of age – BMI 18 to 25 kg/m2 (25 subjects) and 30 to 40 kg/m2 (25 subjects), matched for age and sex. – At maximal lifetime weight. – Weight stable for at least 3 months. Exclusion Criteria:

  • Those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes. – Subjects taking psychiatric or centrally-acting (CNS) medications, or who are diagnosed with a psychiatric or neurological illness, including: depression, anorexia, bulimia, and seizure disorder. – Subjects who have lost weight as a result of dieting, pharmacological treatment, or bariatric surgery. – Weight > 350 lbs or girth > 60 inches (the limits of the MR machine) – Exercise > 30 minutes, 3 times a week. – Alcohol consumption > 2 drinks / day. – Weight > 300 lbs (150 kg) (weight limit for MR machine). – Blood glucose > 100 mg/dL, abnormal creatinine or liver function tests. – Illicit drug use. – Pregnancy. – Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary carbohydrate, protein, or fat intakes. – Those with a contraindication to exposure to strong magnetic fields: presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips. – Those with claustrophobia.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Oregon Health and Science University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jonathan Purnell, Principal Investigator – Oregon Health and Science University
  • Overall Official(s)
    • Jonathan Q. Purnell, M.D., Principal Investigator, Oregon Health and Science University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.